The nonhormonal drug elinzanetant showed substantial benefit for hot flashes, sleep disturbance, and quality of life in data ...

Up to 80% of women experience VMS during menopause, with symptoms lasting a median of 7.4 years. VMS symptoms are often moderate to severe, impacting quality of life significantly. Racial and ...

In other words: Endocrinologists encounter a wide variety of symptoms all day, every day. Here are some surprising ones that concern them the most, even though patients don’t usually recognize ...

The MAA is seeking approval of the candidate for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or adjuvant endocrine therapy.